BioNTech SE
BNTX
$97.27
$4.504.85%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -5.54% | -20.33% | 40.44% | -24.11% | -85.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -5.54% | -20.33% | 40.44% | -24.11% | -85.13% |
| Cost of Revenue | 37.45% | 34.62% | 11.68% | -63.70% | -37.68% |
| Gross Profit | -25.32% | -27.90% | 46.78% | 1,319.37% | -88.99% |
| SG&A Expenses | -11.83% | -8.08% | -0.97% | 31.80% | 8.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -502.15% | 110.26% | 1,070.59% | 1,599.24% | 84.50% |
| Total Operating Expenses | -4.96% | 115.70% | 46.66% | 64.15% | 40.26% |
| Operating Income | 4.74% | -84.39% | -59.71% | -94.41% | -165.42% |
| Income Before Tax | -30.13% | -55.03% | -29.51% | -93.30% | -147.46% |
| Income Tax Expenses | -71.82% | -79.89% | -159.58% | 100.89% | -108.23% |
| Earnings from Continuing Operations | -27.92% | -43.89% | 24.59% | -319.53% | -163.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.92% | -43.89% | 24.59% | -319.53% | -163.51% |
| EBIT | 4.74% | -84.39% | -59.71% | -94.41% | -165.42% |
| EBITDA | 5.81% | -73.48% | -29.61% | -97.18% | -158.09% |
| EPS Basic | -28.02% | -44.02% | 23.63% | -320.57% | -164.06% |
| Normalized Basic EPS | -31.04% | -51.71% | -13.95% | -89.91% | -144.33% |
| EPS Diluted | -28.02% | -43.76% | 23.96% | -320.57% | -164.69% |
| Normalized Diluted EPS | -31.04% | -51.45% | -13.71% | -89.91% | -144.77% |
| Average Basic Shares Outstanding | -0.08% | 0.23% | 0.79% | -0.25% | -0.85% |
| Average Diluted Shares Outstanding | -0.08% | -0.30% | 0.51% | -0.25% | -1.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |